GoodRx Holdings Inc
NASDAQ:GDRX

  • LAST PRICE
    8.3100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    8.0000/ 3
  • Ask / Lots
    8.4400/ 1
  • Open / Previous Close
    0.0000 / 8.3100
  • Day Range
    ---
  • 52 Week Range
    4.1350
    9.3700
  • Volume
    28

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Jul 11, 2024

  • Jul 10, 2024

      Show headlines and story abstract

    • 9:00AM ET on Wednesday Jul 10, 2024 by Business Wire
      Companies Mentioned: GDRX

      GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced the election of Ian T. Clark to its Board of Directors. Mr. Clark brings to GoodRx over 35 years of experience in the pharmaceutical and healthcare industries. He formerly served as Chief Executive Officer of Genentech, a biotechnology company, and previously held leadership positions at Novartis, Sanofi, Ivax Pharmaceuticals and G.D. Searle. Currently, Mr. Clark is on the board of directors of several public biopharmaceutical and biotechnology companies, including Kyverna Therapeutics, Olema Pharmaceuticals, Takeda Pharmaceuticals, Guardant Health and Corvus Pharmaceuticals.

    • 9:00AM ET on Wednesday Jul 10, 2024 by Dow Jones
      Companies Mentioned: GDRX

      Former Genentech CEO brings over 35 years of pharmaceutical and healthcare expertise to GoodRx
      SANTA MONICA, Calif.--(BUSINESS WIRE)--July 10, 2024--
      GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced the election of Ian T. Clark to its Board of Directors. Mr. Clark brings to GoodRx over 35 years of experience in the pharmaceutical and healthcare industries. He formerly served as Chief Executive Officer of Genentech, a biotechnology company, and previously held leadership positions at Novartis, Sanofi, Ivax Pharmaceuticals and G.D. Searle. Currently, Mr. Clark is on the board of directors of several public biopharmaceutical and biotechnology companies, including Kyverna Therapeutics, Olema Pharmaceuticals, Takeda Pharmaceuticals, Guardant Health and Corvus Pharmaceuticals.

Peers Headlines